Tiziana Life Sciences shares surge 10.26% premarket on positive preclinical data showing reduced neuroinflammation and cognitive benefits.

Tiziana Life Sciences surged 10.26% in premarket trading following the release of positive preclinical data on its investigational therapy, intranasal foralumab. The findings indicated that the therapy reduced neuroinflammation, enhanced neurogenesis, and showed potential in reversing aspects of brain aging in preclinical models. The results were highlighted by the company’s Scientific Advisory Board chairman and CEO, reinforcing the treatment’s mechanism and supporting ongoing clinical trials for conditions including Alzheimer’s and multiple sclerosis. The news generated optimism about the drug’s potential in addressing age-related neurological disorders and bolstered investor confidence in Tiziana’s pipeline.